121 results
P
Laparoscopic Roux-en-Y gastric bypass, laparoscopic sleeve gastrectomy
I/C
Laparoscopic Roux-en-Y gastric bypass, laparoscopic sleeve gastrectomy, Laparoscopic Roux-en-Y gastric bypass vs. laparoscopic sleeve gastrectomy
O
Excess weight loss, Type 2 diabetes mellitus resolution, Postoperative complication and reoperation rates, Dyslipidemia, Hypertension, Gastroesophageal reflux disease
P
monolithic translucent Y-TZP ceramics
I/C
hydrothermal aging, aged Y-TZP ceramics
O
translucency parameter (TP), L*
P
FTSF, V-Y closure, perforator flap, non-perforator flap
I/C
separately combined full-thickness skin graft (FTSG), FTSG method based on V-Y closure, perforator flap, non-perforator flap
O
adapted FRFF size, postoperative complications
P
morbid obesity patients
I/C
laparoscopic sleeve gastrectomy (LSG), Roux-en-Y laparoscopic gastric bypass (RYLGB)
O
weight loss, resolution of comorbidities, postoperative complications, operative time, hospital stay, and improvement in quality of life
P
patients with advanced cancer
I/C
receiving immune checkpoint inhibitors (ICIs), sarcopenia vs. no sarcopenia
O
response rate, 1-y progression-free survival (PFS) rate, 1-y overall survival (OS) rate, hazard ratios (HRs) of PFS and OS
P
Y-TZP ceramics
I/C
low-temperature degradation (LTD), steam autoclave aging
O
surface roughness
P
people with obesity
I/C
sleeve gastrectomy (SG), Roux-en-Y gastric bypass (RYGB)
O
incidence rates of cholelithiasis
P
patients undergoing total gastrectomy for gastric cancer
I/C
J-pouch (JP) reconstruction, standard Roux-en-Y (RY) esophagojejunostomy
O
dumping syndrome, heartburn symptoms
P
patients with type 2 diabetes (T2D) and overweight or obesity
I/C
Roux-en-Y gastric bypass (RYGB), medical therapy
O
T2D remission, achieving American Diabetes Association's (ADA's) treatment goal
P
Laparoscopic sleeve gastrectomy (SG)
I/C
Roux-en-Y gastric bypass (RYGB), Insufficient weight loss (IWL) and gastroesophageal reflux disease (GERD)
O
Indication-specific weight loss and diabetes remission